Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease

Journal of the American College of Cardiology

Volumn 64, Issue 3, 2014, Pages 332-333

  Han, Yaling ^a  

^a Shenyang Northern Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ROSUVASTATIN;

CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REHYDRATION; RISK ASSESSMENT; RISK REDUCTION; DISEASE ASSOCIATION; DRUG EFFECT; RENAL PROTECTION; RISK FACTOR;

ACUTE KIDNEY INJURY; ANGIOGRAPHY; CONTRAST MEDIA; DIABETES MELLITUS, TYPE 2; FEMALE; FLUOROBENZENES; HUMANS; MALE; PYRIMIDINES; RENAL INSUFFICIENCY, CHRONIC; SULFONAMIDES;

EID: 84904569261     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.04.039     Document Type: Letter

References (2)

1. Y. Han, G. Zhu, and L. Han et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease J Am Coll Cardiol 63 2014 62 70
2. S.B. King 3rd, S.C. Smith Jr., and J.W. Hirshfeld Jr. et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209